Rotavirus vaccine (RotaTeq®)

被引：18

作者：

Keating G.M. ^{[1
,2
]}

机构：

[1] Adis International Inc., Yardley, PA

[2] Adis International Inc., Yardley, PA 19067

来源：

Pediatric Drugs | 2006年 / 8卷 / 3期

关键词：

Placebo Recipient; Intussusception; Protective Efficacy; Pertussis Vaccine; Seroconversion Rate;

D O I：

10.2165/00148581-200608030-00008

中图分类号：

学科分类号：

摘要：

▲ RotaTeq® is a live, oral, pentavalent human-bovine reassortant rotavirus vaccine approved for use in the prevention of G1-G4 rotavirus gastroenteritis in infants and children. ▲ Rotavirus vaccine demonstrated good immunogenicity in healthy infants. ▲ Three oral doses of rotavirus vaccine had a protective efficacy against G1-G4 rotavirus gastroenteritis of any severity of 74%, and a protective efficacy against severe G1-G4 rotavirus gastroenteritis of 98%, in the randomized, double-blind, placebo-controlled, multicenter REST (Rotavirus Efficacy and Safety Trial) study; the per-protocol efficacy analysis included >4500 infants. ▲ Healthcare resource use was reduced by rotavirus vaccine, with a 94.5% reduction in the incidence of hospitalization or emergency department care because of G1-G4 rotavirus gastroenteritis. This analysis of the REST trial included >57 000 infants. ▲ Rotavirus vaccine did not increase the risk of intussusception within 42 days of any dose, according to an analysis of the REST trial including almost 70 000 infants. Rotavirus vaccine and placebo were associated with serious adverse events in <3% of infants in either group. © 2006 Adis Data Information BV. All rights reserved.

引用

页码：197 / 202

页数：5

共 20 条

[1]

Proceedings of the Sixth International Rotavirus Symposium, (2004)

[2]

Widdowson M.-A., Bresee J.S., Gentsch J.R., Et al., Rotavirus disease and its prevention, Curr Opin Gastroenterol, 21, 1, pp. 26-31, (2005)

[3]

CDC's Advisory Committee Recommends New Vaccine to Prevent Rotavirus: Media Release [Online]

[4]

Glass R.I., Bresee J.S., Parashar U.D., Et al., The future of rotavirus vaccines: A major setback leads to new opportunities, Lancet, 363, 9420, pp. 1547-1550, (2004)

[5]

Treanor J.J., Clark H.F., Pichichero M., Et al., Evaluation of the protective efficacy of a serotype 1 bovine-human rotavirus reassortant vaccine in infants, Pediatr Infect Dis J, 14, 4, pp. 301-307, (1995)

[6]

Clark H.F., Burke C.J., Volkin D.B., Et al., Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation, Pediatr Infect Dis J, 22, 10, pp. 914-920, (2003)

[7]

Clark H.F., Lawley D., Shrager D., Et al., Infant immune response to human rotavirus serotype G1 vaccine candidate reassortant WI79-9: Different dose response patterns to virus surface proteins VP7 and VP4, Pediatr Infect Dis J, 23, 3, pp. 206-211, (2004)

[8]

Ward R.L., Bernstein D.I., Smith V.E., Et al., Rotavirus immunoglobulin A responses stimulated by each of 3 doses of a quadrivalent human/bovine reassortant rotavirus vaccine, J Infect Dis, 189, 12, pp. 2290-2293, (2004)

[9]

Clark H.F., Bernstein D.I., Dennehy P.H., Et al., Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants, J Pediatr, 144, 2, pp. 184-190, (2004)

[10]

RotaTeq® (Rotavirus Vaccine, Live, Oral, Pentavalent): Prescribing Information [Online]

← 1 2 →